BioNxt Solutions (OTCMKTS:BNXTF – Get Free Report) and Profound Medical (NASDAQ:PROF – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability and institutional ownership.
Volatility and Risk
BioNxt Solutions has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500. Comparatively, Profound Medical has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500.
Valuation and Earnings
This table compares BioNxt Solutions and Profound Medical”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BioNxt Solutions | $20,000.00 | 2,234.22 | -$3.88 million | ($0.04) | -9.12 |
| Profound Medical | $16.10 million | 15.44 | -$42.57 million | ($1.41) | -4.85 |
BioNxt Solutions has higher earnings, but lower revenue than Profound Medical. BioNxt Solutions is trading at a lower price-to-earnings ratio than Profound Medical, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
47.9% of Profound Medical shares are owned by institutional investors. 1.5% of Profound Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Profitability
This table compares BioNxt Solutions and Profound Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BioNxt Solutions | N/A | N/A | -709.36% |
| Profound Medical | -264.45% | -90.28% | -73.94% |
Analyst Recommendations
This is a breakdown of recent ratings and target prices for BioNxt Solutions and Profound Medical, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BioNxt Solutions | 0 | 0 | 0 | 0 | 0.00 |
| Profound Medical | 1 | 0 | 1 | 0 | 2.00 |
Profound Medical has a consensus price target of $12.00, suggesting a potential upside of 75.44%. Given Profound Medical’s stronger consensus rating and higher possible upside, analysts clearly believe Profound Medical is more favorable than BioNxt Solutions.
Summary
Profound Medical beats BioNxt Solutions on 8 of the 14 factors compared between the two stocks.
About BioNxt Solutions
BioNxt Solutions Inc. engages in generation drug formulations and delivery system in Korea, Austria, Germany, and Switzerland. The company provides drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications. It offers point-of-care diagnostic, including covid-19 PCR diagnostic kit, a covid rapid test; peri-implantitis Oral Biosensor, allows early detection of infection associated with dental implants; and H1N1 (Swine Flu) and H5N1 (Avian Flu) oral biosensors for early detection of highly pathogenic influenza a strains. In addition, the company offers psychedelic medicine to treat mental health-related medical conditions, including depression, anxiety, addiction, and trauma-related stress disorder. Further, it provides analytical testing and consulting services. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.
About Profound Medical
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.
Receive News & Ratings for BioNxt Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNxt Solutions and related companies with MarketBeat.com's FREE daily email newsletter.
